Progressive multiple sclerosis

12 trials 7 recruiting MedDRA PT
12 Registered trials
7 Recruiting
11 Unique sponsors
25 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 5
N Neurology/Psychiatry (ATC N) 2
H Endocrinology (ATC H) 1
R Respiratory (ATC R) 1
A Gastroenterology (ATC A) 1
P Parasitology (ATC P) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 16 substances
Monoclonal antibody (immune, humanized) 2 substances
Monoclonal antibody (chimeric) 2 substances
Interferon 2 substances
Monoclonal antibody (human) 1 substance
Corticosteroid 1 substance
Analgesic / antipyretic 1 substance
Phase III: 1 Phase II: 7 Phase IV: 2 Phase I (Other): 2

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

1 trial
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506429-13-00 7 countries 2018 n=520
    Ended

Phase II

7 trials
  • Idorsia Pharmaceuticals Ltd. Commercial
    ACT-1004-1239
    2025-522922-11-00 1 country 2026 n=32
    Recruiting
  • Immunic AG Commercial
    VIDOFLUDIMUS CALCIUM
    2024-514617-35-00 6 countries 2021 n=230
    Recruiting
  • Kyverna Therapeutics Inc. Commercial
    KYV-101; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; UBLITUXIMAB
    2024-511168-10-00 4 countries n=88
    Pending
  • Antwerp University Hospital Academic
    DIMETHYL FUMARATE; FINGOLIMOD; GLATIRAMER ACETATE; INTERFERON BETA-1A; METFORMIN HYDROCHLORIDE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OZANIMOD; PEGINTERFERON BETA-1A; PONESIMOD; RECOMBINANT INTERFERON BETA-1B; SIPONIMOD; TERIFLUNOMIDE
    2023-503190-38-00 1 country 2023 n=120
    Ended
  • Ospedale San Raffaele S.r.l. Academic
    HUMAN NEURONAL PROGENITOR/STEM CELLS
    2024-511028-15-00 1 country 2025 n=86
    Recruiting
  • University Of Tartu Academic
    IMP not specified
    2024-517336-21-00 1 country 2025 n=34
    Recruiting
  • Varsinais-Suomen hyvinvointialue Academic
    HYDROXYCHLOROQUINE SULFATE
    2025-522573-11-00 1 country n=34
    Pending

Phase IV

2 trials
  • Azienda Ospedaliera Universitaria Integrata Verona Academic
    SIPONIMOD
    2024-512283-65-00 1 country 2023 n=40
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona Academic
    SIPONIMOD; SIPONIMOD FUMARIC ACID
    2024-518374-13-00 1 country 2022 n=60
    Recruiting

Phase I (Other)

2 trials
  • Autolus Limited Commercial
    IMP not specified
    2024-519552-93-00 1 country 2025 n=3
    Recruiting
  • Celgene Corp. Commercial
    IMP not specified
    2023-507820-22-00 4 countries 2024 n=56
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Azienda Ospedaliera Universitaria Integrata Verona Academic 2 Phase IV 2
Autolus Limited Commercial 1 Phase I (Other) 1
Celgene Corp. Commercial 1 Phase I (Other) 0
Idorsia Pharmaceuticals Ltd. Commercial 1 Phase II 1
Immunic AG Commercial 1 Phase II 1
Kyverna Therapeutics Inc. Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Antwerp University Hospital Academic 1 Phase II 0
Ospedale San Raffaele S.r.l. Academic 1 Phase II 1
University Of Tartu Academic 1 Phase II 1
Varsinais-Suomen hyvinvointialue Academic 1 Phase II 0
New trials by year
2021
1
2022
1
2023
2
2024
1
2025
3
2026
1
← All indication landscapes